Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: Results from the Treating to New Targets (TNT) Trial

American Heart Journal

Volumn 156, Issue 4, 2008, Pages 698-705

  Mark, Daniel B ^a   Knight, J David ^a   Cowper, Patricia A ^a   Davidson Ray, Linda ^a   Anstrom, Kevin J ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG MEGADOSE; EARLY DIAGNOSIS; ECONOMIC ASPECT; FEMALE; FOLLOW UP; HEART ARREST; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; INTERMETHOD COMPARISON; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; SECONDARY PREVENTION; STROKE; UNITED STATES;

AGED; CORONARY ARTERY DISEASE; FEMALE; HEPTANOIC ACIDS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICARE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; PYRROLES; UNITED STATES;

EID: 52949152875     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.05.032     Document Type: Article

References (20)

1. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
2. Mark D.B., and Hlatky M.A. Medical economics and the assessment of value in cardiovascular medicine: Part I. Circulation 106 (2002) 516-520
3. Cannon C.P., Steinberg B.A., Murphy S.A., et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48 (2006) 438-445
4. Chan P.S., Nallamothu B.K., Gurm H.S., et al. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation 115 (2007) 2398-2409
5. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
6. Mark D.B., Nelson C.L., Anstrom K.J., et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 114 (2006) 135-142
7. Mark D.B., Harrington R.A., Lincoff A.M., et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST elevation acute coronary syndromes. Circulation 101 (2000) 366-371
8. 2004 Drug Topics Red Book (2004), Medical Economics Data, Montvale (NJ)
9. Drugstore.com online pharmacy. 2007; Available at http://www.drugstore.com/. Last accessed June 12, 2007.
10. Costco Wholesale Corporation. 2007; Available at http://www.costco.com/. Last accessed June 12, 2007.
11. Mahoney E.M., Jurkovitz C.T., Chu H., et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 288 (2002) 1851-1858
12. Cohen D.J., Bakhai A., Shi C., et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 110 (2004) 508-514
13. Gotto A.M., Boccuzzi S.J., Cook J.R., et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. Am J Cardiol 86 (2000) 1176-1181
14. Pedersen T.R., Kjekshus J., Berg K., et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 93 (1996) 1796-1802
15. Tsevat J., Kuntz K.M., Orav E.J., et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 141 (2001) 727-734
16. Schwartz G.G., Ganz P., Waters D., et al. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Am J Cardiol 92 (2003) 1109-1112
17. Mihaylova B., Briggs A., Armitage J., et al. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet 365 (2005) 1779-1785
18. Johannesson M., Jonsson B., Kjekshus J., et al., for the Scandinavian Simvastatin Survival Group. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 336 (1997) 332-336
19. Prosser L.A., Stinnett A.A., Goldman P.A., et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 132 (2000) 769-779
20. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445